California Life Sciences (CLS)

California Life Sciences is excited to announce the release of the latest edition of 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞: 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐒𝐭𝐚𝐫𝐭𝐮𝐩 𝐑𝐨𝐚𝐝 𝐭𝐨 𝐒𝐮𝐜𝐜𝐞𝐬𝐬! This edition features inspiring stories from founders alongside valuable insights designed to help support more startups on their path from idea to exit. 🙌 At CLS, we celebrate the creativity and courage of startup founders in California’s dynamic innovation landscape. We are committed to supporting these entrepreneurs by providing the resources they need to focus on what they do best: advancing science and bringing innovative solutions to patients. Join us in celebrating the stories of creativity, courage, and collaboration that drive our industry forward! 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://bit.ly/4gZojKl

It’s now or never! Voting closes today at 5pm PT. Don't miss your opportunity to support the outstanding finalists at this year's Pantheon Awards. Discover their groundbreaking achievements and make your voice heard. Every vote counts, and your support can make a difference in recognizing innovation in the life sciences field. Let’s celebrate excellence together! 🗳️ CAST YOUR VOTE: https://bit.ly/3ZLqScG

This award is presented to an individual who demonstrates their commitment to make the world a better place by employing new, innovative business models and practices in support of their team and the life sciences. We present to you the Leadership Award finalists for the 2024 Pantheon Awards: 🗣️ Bobak Azamian, MD, PhD: Cofounded Tarsus Pharmaceuticals, Inc. in 2016 and currently serves as CEO and Chairman. Under his leadership, Tarsus secured FDA approval for XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment for Demodex blepharitis. 🗣️ David Persing, MD PhD: EVP/Chief Medical Officer at Cepheid, where he has focused on advancements in molecular diagnostics for addressing the global challenges of emerging infectious diseases. 🗣️ Matthew Rabinowitz, PhD: Co-founder and Executive Chairman of Natera, previously served as its CEO from 2005 – 2018. With a Ph.D. from Stanford, he's led groundbreaking research in non-invasive prenatal testing and oncology. Get inspired by their leadership and ensure your voice is heard—vote by Oct 15! 🗳️ 𝐕𝐎𝐓𝐄: https://bit.ly/3PJqvIQ

Tomorrow is the last day to apply for our Investor Partnering Forum, taking place December 10 in South San Francisco. This is a unique opportunity for emerging startups to connect with a curated group of investors for one-on-one, 20-minute in-person meetings. Don’t miss this opportunity – applications close at 5pm tomorrow! 𝐋𝐄𝐀𝐑𝐍 𝐌𝐎𝐑𝐄 & 𝐀𝐏𝐏𝐋𝐘: https://bit.ly/3Ni4vUK

California Life Sciences (CLS)'s Sam Chung, Vice President of State Government Relations, helps demystify the critical and long-time role AI plays in advancing groundbreaking cures. AI allows scientists and researchers to expand their horizons in the drug discovery process to bring breakthrough medicines more quickly to patients. AI is also an incredible tool that helps the life sciences to optimize our clinical trials to get the best participation possible for more effective treatments for all people. Thank you, Capitol Weekly, for providing CLS the opportunity to share the life sciences perspective on AI in healthcare.

The Convergent Technology Award is presented to a medical device, digital health, or medical diagnostic company for their innovative work and impact on the California life sciences sector. Presenting the 2024 finalists: 🔬 Moon Surgical: Shaping the future of the OR with its efficient, sustainable, and digitalized Maestro System. 🔬 Osso VR: Creates award-winning XR training experiences used by leading healthcare companies and hospital systems. 🔬 Cooler Heads Care: The only solution that makes it profitable for infusion centers to offer chemotherapy patients scalp cooling so they can keep their hair. Get inspired by their innovations and be part of the decision—vote by Oct 15! 🗳️ 𝐕𝐎𝐓𝐄: https://bit.ly/3TVbEy7

California Life Sciences released the following statement expressing concerns with the impact the FTC’s final rule on premerger notification rules implementing the Hart-Scott-Rodino (HSR) Act, can have on the collaborative life sciences ecosystem in California. “The resulting burden and uncertainty of the agencies’ approach will disincentivize M&A and hamper investment in the research and development that leads to new treatments and cures. This will be especially devastating to our early-stage innovators and startups for whom M&A represents a path to necessary resources, investments and infrastructure needed to advance breakthroughs from the lab to patients.“ Read the full statement here: https://bit.ly/3U7NIrf

Last week, California Life Sciences and Johnson & Johnson gathered industry leaders, innovators, and investors in the industry for an inspiring summit focused on harnessing AI’s potential to transform pharmaceutical research and development. 🔬 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: 𝐀𝐈-𝐃𝐫𝐢𝐯𝐞𝐧 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲: We learned how AI algorithms are accelerating the identification of potential drug candidates, significantly reducing time-to-market. 𝐃𝐚𝐭𝐚 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: Experts emphasized the importance of integrating diverse data sources, enabling more comprehensive insights, and fostering collaboration across disciplines. 𝐄𝐭𝐡𝐢𝐜𝐬 𝐚𝐧𝐝 𝐂𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞: Engaging discussions addressed the ethical considerations and regulatory challenges that come with implementing AI in drug development. 𝐑𝐞𝐚𝐥-𝐖𝐨𝐫𝐥𝐝 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: Several case studies showcased successful AI implementations, illustrating tangible benefits in efficiency and cost savings. Future of R&D: The consensus? AI is not just a tool; it’s a game changer. As we continue to embrace these technologies, the potential for breakthroughs in patient care is immense. A huge thank you to our sponsors, Avantor and Danaher Corporation speakers, pitch finalists, and attendees for making this event a success. Together, we are shaping the future of pharmaceutical innovation. #AISummit #PharmaceuticalR&D #Innovation #Healthcare #AI #DrugDiscovery #FutureOfMedicine

Are you a life sciences entrepreneur looking to grow your business? The National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program offers approximately $200 million annually to biotech startups with no strings attached. Join NCI SBIR Director of Investor Relations Brittany Connors, PMP and Program Director Saroj Regmi, PhD for an informative webinar to learn how to: ➡️ Obtain SBIR funding: Explore funding opportunities that can amount to over $7 million per project. ➡️ Navigate the review process: Understand the ins and outs of the SBIR evaluation process. ➡️ Commercialize your innovation: Gain insights into bringing your healthcare technology to market. ➡️ Learn about other commercialization resources: Discover additional resources and tools provided by the NCI SBIR Development Center to support your business growth.   𝗥𝗘𝗚𝗜𝗦𝗧𝗘𝗥 𝗛𝗘𝗥𝗘: https://bit.ly/3XOHXQm

This award highlights up-and-coming California-based innovators who are making strides towards transforming the life sciences landscape. Meet the Emerging Innovation Award finalists for the 2024 Pantheon Awards: 💡 AltruBio Inc.: A clinical-stage biotechnology company developing novel Immune Checkpoint Enhancers (ICE) to address pressing medical needs of patients with autoimmune and inflammatory diseases. 💡 Cellares: The first Integrated Development and Manufacturing Organization (IDMO), accelerates global access to life-saving cell therapies with its Cell Shuttle™ and Cell Q platforms. 💡 Mammoth Biosciences: A biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Discover their remarkable innovations and cast your vote by Oct 15! 🗳️ 𝐕𝐎𝐓𝐄: https://bit.ly/4gUGUH6